Despite the absence of statistically significant efficacy against clinical malaria, an intriguing finding was the observation of a marginally significant reduction in cases of severe malaria amongst malaria vaccinees at day 120 of follow-up in a secondary analysis of severe malaria as an endpoint.
← all excerpts
First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children.
1
—
—